SAGE Therapeutics, Inc.

( )
SAGE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
PTLAPortola Pharmaceuticals, Inc. -0.50%17.866.5%$171.15m
HZNPHorizon Therapeutics Plc -1.66%49.896.5%$147.25m
CTLTCatalent, Inc. -1.40%76.642.3%$136.90m
MYOKMyoKardia, Inc. 0.71%103.021.8%$136.53m
BHCBausch Health Cos., Inc. 3.68%19.160.0%$128.68m
VRXValeant Pharmaceuticals International, Inc. 3.68%19.1614.1%$112.74m
UTHRUnited Therapeutics Corp. 1.98%120.2814.3%$72.90m
ICPTIntercept Pharmaceuticals, Inc. 1.77%73.5416.8%$62.73m
JAZZJazz Pharmaceuticals Plc 0.04%119.372.4%$59.79m
ARGXargenx SE 2.79%225.410.0%$57.13m
GWPHGW Pharmaceuticals Plc 1.65%124.786.2%$55.16m
AMRNAmarin Corp. Plc -2.19%6.711.6%$53.25m
AXSMAxsome Therapeutics, Inc. 0.01%76.991.9%$49.15m
PRGOPerrigo Co. Plc 1.21%55.436.8%$42.75m
ICLRICON plc 0.77%169.744.3%$42.50m

Company Profile

SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.